Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, Kumar U, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy JS, Jahreis A, Genovese MC, Mozaffarian N, Landewé RBM, Bae SC, Keystone EC, Nash P. Combe B, et al. Among authors: bartok b. Ann Rheum Dis. 2021 Jul;80(7):848-858. doi: 10.1136/annrheumdis-2020-219214. Epub 2021 Jan 27. Ann Rheum Dis. 2021. PMID: 33504485 Free PMC article. Clinical Trial.
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T. Genovese MC, et al. Among authors: bartok b. JAMA. 2019 Jul 23;322(4):315-325. doi: 10.1001/jama.2019.9055. JAMA. 2019. PMID: 31334793 Free PMC article. Clinical Trial.
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
Takeuchi T, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Genovese MC, Kalunian K, Walker D, Gottenberg JE, de Vlam K, Bartok B, Pechonkina A, Kondo A, Gao J, Guo Y, Tasset C, Sundy JS, Tanaka Y. Takeuchi T, et al. Among authors: bartok b. Mod Rheumatol. 2022 Jan 5;32(1):59-67. doi: 10.1080/14397595.2020.1859675. Mod Rheumatol. 2022. PMID: 33274687 Clinical Trial.
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.
Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landewé RB, Atsumi T, Burmester GR. Westhovens R, et al. Among authors: bartok b. Ann Rheum Dis. 2021 Jun;80(6):727-738. doi: 10.1136/annrheumdis-2020-219213. Epub 2021 Jan 15. Ann Rheum Dis. 2021. PMID: 33452004 Free PMC article. Clinical Trial.
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3.
Aletaha D, Westhovens R, Gaujoux-Viala C, Adami G, Matsumoto A, Bird P, Messina OD, Buch MH, Bartok B, Yin Z, Guo Y, Hendrikx T, Burmester GR. Aletaha D, et al. Among authors: bartok b. RMD Open. 2021 Aug;7(2):e001621. doi: 10.1136/rmdopen-2021-001621. RMD Open. 2021. PMID: 34385364 Free PMC article. Clinical Trial.
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
Winthrop KL, Tanaka Y, Takeuchi T, Kivitz A, Matzkies F, Genovese MC, Jiang D, Chen K, Bartok B, Jahreis A, Besuyen R, Burmester GR, Gottenberg JE. Winthrop KL, et al. Among authors: bartok b. Ann Rheum Dis. 2022 Feb;81(2):184-192. doi: 10.1136/annrheumdis-2021-221051. Epub 2021 Nov 5. Ann Rheum Dis. 2022. PMID: 34740884 Free PMC article.
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
Tanaka Y, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Combe BG, Kivitz AJ, Bae SC, Keystone EC, Nash P, Matzkies F, Bartok B, Pechonkina A, Kondo A, Ye L, Guo Y, Tasset C, Sundy JS, Takeuchi T. Tanaka Y, et al. Among authors: bartok b. Mod Rheumatol. 2022 Feb 28;32(2):263-272. doi: 10.1093/mr/roab030. Mod Rheumatol. 2022. PMID: 34910188 Clinical Trial.
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
Atsumi T, Tanaka Y, Matsubara T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Westhovens R, Ching DWT, Messina OD, Burmester GR, Bartok B, Pechonkina A, Kondo A, Yin Z, Guo Y, Tasset C, Sundy JS, Takeuchi T. Atsumi T, et al. Among authors: bartok b. Mod Rheumatol. 2022 Feb 28;32(2):273-283. doi: 10.1093/mr/roab021. Mod Rheumatol. 2022. PMID: 34910203 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 34922366
Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
Meng A, Anderson K, Nelson C, Ni L, Chuang SM, Bellanti F, Chang P, Comisar C, Kearney BP, Bartok B, Mathias A. Meng A, et al. Among authors: bartok b. Br J Clin Pharmacol. 2022 Jul;88(7):3211-3221. doi: 10.1111/bcp.15239. Epub 2022 Feb 14. Br J Clin Pharmacol. 2022. PMID: 35072287 Free PMC article. Clinical Trial.
37 results